The analogue BDC-2034, targeting CEACAM5, has shown anti-tumor activity in vivo at low dose (0.5 mg/kg), activation of the innate immune system and reprogramming of intra-tumor myeloid, thus supporting its clinical development (Table 3) [179, 180]. The gene discussed is CEACAM5; the disease is neoplasm.